

## Avacta Group plc

("Avacta" or the "Group" or the "Company")

### Result of AGM

**LONDON and PHILADELPHIA- July, 2 2025** - Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces that at the Annual General Meeting (AGM) held this morning, all resolutions were duly passed by shareholders (with the exception of Resolution 3 which was not put to the meeting).

The results of the voting at the AGM are outlined in the table below and the presentation materials are available on the Company's website [here](#).

Resolution	For		Against		Withheld
	Votes	%	Votes	%	Votes
1	69,286,714	99.84%	111,935	0.16%	2,231,336
2	52,723,506	77.25%	15,527,142	22.75%	3,379,337
3	See above	-	See above	-	See above
4	70,378,158	99.32%	482,896	0.68%	768,931
5	68,687,888	98.79%	843,416	1.21%	2,098,681
6	68,241,916	97.50%	1,747,126	2.50%	1,640,943
7	70,242,593	99.58%	293,323	0.42%	1,094,069
8	61,988,039	90.99%	6,139,673	9.01%	3,502,273
9	64,805,029	98.71%	850,095	1.29%	5,974,861
10	65,957,356	97.83%	1,462,237	2.17%	4,210,392
11	64,414,344	96.66%	2,229,203	3.34%	4,986,438
12	64,418,047	96.71%	2,189,948	3.29%	5,021,990
13	67,217,793	99.14%	580,188	0.86%	3,832,004

Although all the resolutions were passed, the Board of Avacta notes that more than 20% of votes were cast against Resolution 2. The Board will continue to engage with shareholders in the periods ahead and remains committed to open and constructive dialogue in order to understand shareholders' views. To this end, shareholders who voted against resolution 2 can email any views to [avacta@icrhealthcare.com](mailto:avacta@icrhealthcare.com).

-Ends -

For further information from Avacta Group plc, please contact:

**Avacta Group plc**  
Michael Vinegrad,  
Group Communications Director

<https://avacta.com/>

**Peel Hunt (Nomad and Joint Broker)**  
James Steel / Chris Golden

[www.peelhunt.com](http://www.peelhunt.com)

**Panmure Liberum (Joint Broker)**  
Emma Earl / Will Goode / Mark Rogers

[www.panmureliberum.com](http://www.panmureliberum.com)

**Zeus (Joint Broker)**  
James Hornigold / George Duxberry  
Dominic King

[www.zeuscapital.co.uk](http://www.zeuscapital.co.uk)

**ICR Healthcare**  
Mary-Jane Elliott / Jessica Hodgson /  
Stephanie Cuthbert

[avacta@icrhealthcare.com](mailto:avacta@icrhealthcare.com)

**Investor Contact**

Renee Leck

[renee@thrustsc.com](mailto:renee@thrustsc.com)

**Media Contact**

Carly Scaduto  
Carly Scaduto Consulting

[Carly@carlyscadutoconsulting.com](mailto:Carly@carlyscadutoconsulting.com)

**About Avacta - <https://avacta.com/>**

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGEASXAESASEFA